Shares of Dare Bioscience DARE decreased 2.4% in pre-market trading after the company reported Q4 results.
Quarterly Results
Earnings per share fell 4.76% year over year to ($0.22), which missed the estimate of ($0.13).
Revenue of $0 unchanged by 0.00% year over year, which missed the estimate of $520,000.
Guidance
Dare Bioscience hasn't issued any earnings guidance for the time being.
Revenue guidance hasn't been issued by the company for now.
How To Listen To The Conference Call
Date: Mar 30, 2021
Time: 04:30 PM
ET Webcast URL: https://edge.media-server.com/mmc/p/8uh76a7g
Recent Stock Performance
52-week high: $3.85
52-week low: $0.82
Price action over last quarter: Up 49.09%
Company Profile
Dare Bioscience Inc is a clinical-stage biopharmaceutical company focused on women's reproductive health. The products of the company are related to fertility, vaginal health, and contraception. Ovaprene is a product designed by the company to provide multiple weeks of contraceptive protection without the use of hormones.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
